The biotech bi-weekly: accelerating antibody discovery, developing gene therapy for prion disease and advancing genomic medicine
In this week’s edition of the biotech bi-weekly, learn more about CRAIC technologies’ 5D Spectral Surface Mapping solution, which can provide comprehensive insights into the composition, morphology and behavior of materials at the micro and nanoscale, as well as the cutting-edge AI technology accelerating antibody discovery across key therapeutic areas.
Products
CRAIC Technologies introduces 5D Spectral Surface Mapping™
CRAIC Technologies (CA, USA), a leading provider of scientific instrumentation, recently announced the launch of its innovative 5D Spectral Surface Mapping™ solution, designed to empower researchers and industry professionals with advanced microspectroscopy and analytical capabilities for materials science and microscopy applications.
Spectral mapping, a powerful technique combining spectroscopy and microscopy over surfaces, allows researchers to visualize and analyze the spatial distribution of chemical and structural properties within samples with exceptional detail and precision. CRAIC Technologies’ Spectral Mapping solution combines cutting-edge imaging technology with advanced spectral analysis tools to deliver comprehensive insights into the composition, morphology and behavior of materials at the micro and nanoscale.
Read the full release here >>>
Bio-Techne begins shipping Leo – a next-generation high-throughput Simple Western system
Bio-Techne Corporation (MN, USA) has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization.
Read the full release here >>>
Nona Biosciences integrates cutting-edge AI technology to enhance its fully human antibody platform, accelerating antibody discovery across key therapeutic areas
Nona Biosciences (MA, USA), a global biotechnology company providing a total solution from ‘Idea to IND’ (I to ITM), announced the unveiling of its innovative AI-assisted drug discovery engine, Hu-mAtrIxTM. This new platform, powered by advanced artificial intelligence, integrates seamlessly with the company’s proprietary Harbour Mice® technology platform, aiming to accelerate antibody discovery across multiple key therapeutic areas, including neurodegenerative and metabolic diseases.
Read the full release here >>>
Novel computational model predicts effective drug combinations
A computational tool has accurately predicted a drug combination that inhibited triple-negative breast cancer in in vitro experiments.
Partnerships
Golden Helix partners with the Danish healthcare regions to drive advancements in genomic medicine
Golden Helix (MT, USA), a global leader in bioinformatics solutions for next-generation sequencing and precision medicine, has announced a multi-year agreement with all Danish healthcare regions. The agreement aims to enhance the genomic capabilities of multiple laboratories within the regions, supporting critical advancements in cancer and hereditary disease diagnostics.
In a unified effort across Denmark’s healthcare regions, the laboratories are committed to integrating cutting-edge genomic technologies into their clinical workflows to improve patient outcomes. With a longstanding relationship spanning several years, this multi-year agreement solidifies the trust and commitment between Golden Helix and these institutions to drive innovation in genomic medicine.
Read the full release here >>>
Nikon Instruments announces Moffitt Cancer Center as newest Nikon Center of Excellence
Nikon Instruments (NY, USA) has announced the opening of the newest Nikon Center of Excellence at the Moffitt Cancer Center (FL, USA). This prestigious designation underscores Nikon’s commitment to providing cutting-edge imaging technology directly to healthcare facilities such as Moffitt Cancer Center for the purpose of developing better cancer treatments and cures.
Read the full release here >>>
Apertura Gene Therapy supports the Broad Institute in the development of gene therapy for prion disease
Apertura Gene Therapy (NY, USA), a biotechnology company focused on innovative gene therapy solutions, supports the Broad Institute of MIT and Harvard and the Whitehead Institute (both MA, USA) in advancing a gene therapy approach for the treatment of prion disease. The project is led by the Vallabh-Minikel lab at the Broad Institute, which is focused on finding a cure for prion disease, and their approach leverages two cutting-edge technologies: the CHARM platform designed in Jonathan Weissman’s lab (Whitehead Institute), and TfR1 capsid, an engineered AAV designed in the lab of Ben Deverman, Director of Vector Engineering at the Broad Institute and scientific founder of Apertura.
Read the full release here >>>
Rare Disease Day: national genomic medicine programs and recent research
We explore three wide-reaching national programs that have caught our eye as they navigate the human genome and its place in rare disease research, as well as highlight recent publications discussing techniques that have been used to understand rare diseases.
People and publications
Immunai appoints former Pfizer CSO and R&D Chief, Mikael Dolsten, to Board of Directors
Immunai (NY, USA), a leading artificial intelligence biotech company specializing in mapping the human immune system, recently announced the appointment of Mikael Dolsten to its Board of Directors. Dolsten, who served most recently as Pfizer’s Chief Scientific Officer and President of Research & Development for 15 years, brings decades of experience leading drug and vaccine discovery and development. He will support Immunai’s mission to integrate AI into immunology and oncology research, helping drive precise and efficient therapeutic innovation.
Read the full release here >>>
Sapio Sciences expands leadership team to drive growth
Sapio Sciences (MD, USA), the science-awareTM lab informatics platform, today announced key leadership appointments to accelerate drug discovery and redefine AI-driven lab informatics. With the appointment of Mike Hampton as Chief Commercial Officer and the launch of a new Scientific Office, Sapio is reinforcing its commitment to scientific and customer-driven innovation.
